Bromide

Bromide

SCHEMBL5085187

CCCCCCCCCC[N+](CCCC)(CCCC)CCCC.[Br-]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.93
▸ TP53 P04637 1/20 0.93
▸ CYP3A4 P08684 1/20 0.93
▸ ALOX15 P16050 1/20 0.93
▸ TSHR P16473 1/20 0.93
▸ ALOX12 P18054 1/20 0.93
▸ SMN1; SMN2 Q16637 1/20 0.93
▸ HIF1A Q16665 1/20 0.93
▸ HSD17B10 Q99714 1/20 0.93
▸ SLC22A1 O15245 3/20 0.87
▸ SLC22A2 O15244 1/20 0.80
▸ DNM1 Q05193 7/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5084980 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL5085227 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL5087210 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL2733876 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL5088202 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL1347880 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL3028771 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL8586767 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL1507558 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR
Bromide SCHEMBL3916850 1.00 ALDH1A1 (0.93) ALDH1A1TP53CYP3A4ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596911-B2 Providing a mixture comprising water and a hydrocarbon; and contacting with onium compound and amine salt for inhibiting the formation of the hydrocarbon hydrates BAKER HUGHES INCORPORATION 2003-07-22 — — US claimed
US-20250122418-A1 Synergistic Blends Of Anti-Agglomerant Gas Hydrate Inhibitors With Quaternary Alkyl Ammonium Compounds CLARIANT INT LTD (CH) 2025-04-17 — — US disclosed
US-12129427-B2 Synergistic blends of anti-agglomerant gas hydrate inhibitors with quaternary alkyl ammonium compounds CLARIANT INTERNATIONAL LTD (CH) 2024-10-29 — — US disclosed
US-11898091-B2 Synergistic blends of anti-agglomerant gas hydrate inhibitors with quaternary benzyl ammonium compounds CLARIANT INTERNATIONAL LTD (CH) 2024-02-13 — — US disclosed
EP-4073199-A1 SYNERGISTIC BLENDS OF ANTI-AGGLOMERANT GAS HYDRATE INHIBITORS WITH QUATERNARY BENZYL AMMONIUM COMPOUNDS Clariant International Ltd (CH) 2022-10-19 — — EP disclosed
EP-4073195-A1 SYNERGISTIC BLENDS OF ANTI-AGGLOMERANT GAS HYDRATE INHIBITORS WITH QUATERNARY ALKYL AMMONIUM COMPOUNDS Clariant International Ltd (CH) 2022-10-19 — — EP disclosed
US-20210179918-A1 Synergistic Blends Of Anti-Agglomerant Gas Hydrate Inhibitors With Quaternary Benzyl Ammonium Compounds CLARIANT INTERNATIONAL, LTD. (CH) 2021-06-17 — — US disclosed
WO-2021115967-A1 SYNERGISTIC BLENDS OF ANTI-AGGLOMERANT GAS HYDRATE INHIBITORS WITH QUATERNARY ALKYL AMMONIUM COMPOUNDS CLARIANT INTERNATIONAL LTD (CH) 2021-06-17 — — WO disclosed
WO-2021115969-A1 SYNERGISTIC BLENDS OF ANTI-AGGLOMERANT GAS HYDRATE INHIBITORS WITH QUATERNARY BENZYL AMMONIUM COMPOUNDS CLARIANT INTERNATIONAL LTD (CH) 2021-06-17 — — WO disclosed
WO-2021115973-A1 SYNERGISTIC BLENDS OF ANTI-AGGLOMERANT GAS HYDRATE INHIBITORS WITH N-ALKANOYL-POLYHYDROXYALKYLAMINES CLARIANT INTERNATIONAL LTD (CH) 2021-06-17 — — WO disclosed
US-6372154-B1 Luminescent ink for printing of organic luminescent devices CANON KABUSHIKI KAISHA (JP) 2002-04-16 — — US disclosed
EP-0736130-B1 A METHOD FOR INHIBITING THE PLUGGING OF CONDUITS BY GAS HYDRATES SHELL INT RESEARCH (NL) 1998-07-15 — — EP disclosed
US-5648575-A Method for inhibiting the plugging of conduits by gas hydrates SHELL OIL COMPANY (US) 1997-07-15 — — US disclosed
EP-0736130-A1 A METHOD FOR INHIBITING THE PLUGGING OF CONDUITS BY GAS HYDRATES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1996-10-09 — — EP disclosed
US-5460728-A Using quaternary ammonium compound as inhibitor of hydrate formation SHELL OIL COMPANY (US) 1995-10-24 — — US disclosed
WO-1995017579-A1 A METHOD FOR INHIBITING THE PLUGGING OF CONDUITS BY GAS HYDRATES SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1995-06-29 — — WO disclosed
EP-0340703-B1 PROCESS FOR THE PRODUCTION OF FORMYL CYCLOPROPANE BASF Aktiengesellschaft (DE) 1992-03-25 — — EP disclosed
US-5053550-A PREPARATION OF FORMYLCYCLOPROPANE BASF AKTIENGESELLSCHAFT (DE) 1991-10-01 — — US disclosed
EP-0340703-A1 Process for the production of formyl cyclopropane BASF Aktiengesellschaft (DE) 1989-11-08 — — EP disclosed
EP-0099259-A1 Process for producing surface-treated ferromagnetic particles KONICA CORPORATION (JP) 1984-01-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129427-B2 Synergistic blends of anti-agglomerant gas hydrate inhibitors with quaternary alkyl ammonium compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1, MTDH ALDH1A1 3129/4885TP53 1612/4885CYP3A4 3466/4885
US-11898091-B2 Synergistic blends of anti-agglomerant gas hydrate inhibitors with quaternary benzyl ammonium compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC1, AQP1 ALDH1A1 3641/4885TP53 2433/4885CYP3A4 3391/4885
US-20250122418-A1 Synergistic Blends Of Anti-Agglomerant Gas Hydrate Inhibitors With Quaternary Alkyl Ammonium Compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDHD5, AQP1 ALDH1A1 3650/4885TP53 647/4885CYP3A4 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback